Leathley M.J., Goudie A.J.
Department of Psychology, University of Liverpool, P.O. Box 147, Liverpool L69 3BX, UK.
Behav Pharmacol. 1992 Feb;3(1):51-56. doi: 10.1097/00008877-199203010-00008.
Effects of the 5-HT3 antagonist ICS 205-930 on chlordiazepoxide (CDP) withdrawal were assessed in rats treated for 21 days with doses of CDP up to 40mg/kg/day (b.i.d.). Withdrawal signs recorded were body weight and 24h food intake, which both fell during withdrawal and then recovered. ICS 205-930 (0.001-1.0mg/kg) was administered b.i.d. during withdrawal. At no dose over the wide range tested did ICS 205-930 reduce withdrawal signs. These data contrast with published findings with the 5-HT3 antagonist ondanestron, some of which indicated that ondansetron completely alleviated the "anxiogenic" suppression of exploratory behaviour observed during benzodiazepine (BZ) withdrawal. Possible reasons for these differing findings are discussed. Collectively, these findings suggest that 5-HT3 antagonists may have limited utility in the clinical treatment of BZ withdrawal.
在以高达40mg/kg/天（每日两次）的氯氮卓（CDP）剂量治疗21天的大鼠中，评估了5-羟色胺3（5-HT3）拮抗剂ICS 205-930对氯氮卓戒断的影响。记录的戒断症状包括体重和24小时食物摄入量，二者在戒断期间均下降，然后恢复。在戒断期间，ICS 205-930（0.001 - 1.0mg/kg）每日给药两次。在测试的广泛剂量范围内，ICS 205-930均未减轻戒断症状。这些数据与已发表的关于5-HT3拮抗剂昂丹司琼的研究结果形成对比，其中一些研究表明昂丹司琼完全缓解了在苯二氮卓（BZ）戒断期间观察到的对探索行为的“致焦虑”抑制。讨论了这些不同研究结果的可能原因。总体而言，这些研究结果表明5-HT3拮抗剂在BZ戒断的临床治疗中可能效用有限。
